This page contains a Flash digital edition of a book.
Dr. Silverberg Mount Sinai Hospital Investment in 2011/12: $125,000

Dr. Beck

University of Calgary Investment in 2011/12: $125,000

Dr. Asselin

University of Sherbrooke Investment in 2011/12: $125,000

Dr. Silverberg Mount Sinai Hospital Investment in 2011/12: $62,500

Dr. Jones

Hospital for Sick Children Investment in 2011/12: $62,500

Dr. Silverberg is evaluating the genes and microbes that are associated with the onset and recurrence of inflammation following surgery. This may help healthcare professionals predict which CD patients are likely to develop recurrent inflammation after surgery.

Many of the genes associated with an increased risk of IBD are involved in immune response. Dr. Beck is studying how mutations in a particular gene decrease our ability to kill some bacteria and induce hyper-inflammation.

Dr. Asselin is studying the role of proteins, which control genetic and epigenetic information in gut cells, during inflammation. In the long term, this research program may lead to better treatments for IBD.

Dr. Silverberg is trying to find genetic markers that will, with a simple blood test, enable health care professionals screen individuals with CD most likely to develop severe or mild disease. This will enable more personalized therapies that will benefit patients’ quality of life and reduce complications.

Two gene mutations associated with CD are Nod2 (which senses bacteria within the cell) and ATG16L1 (which is needed for digesting and recycling material inside the cell). Dr. Jones is studying how these two genes might be involved in causing disease in order to develop better therapies to treat and prevent IBD.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24